1. Indications and Usage
\nAcute Agitation in Schizophrenia:
\nTreatment of acutely agitated patients with schizophrenia for rapid tranquilization.
\nAcute Agitation in Bipolar I Disorder:
\nTreatment of acutely agitated patients with Bipolar I Disorder (Mania or Mixed Episodes).
\n2. Dosage and Administration
\nRoute of Administration:
\nFor Intramuscular (IM) Injection ONLY.
\nNote: Not for intravenous (IV) or subcutaneous administration.
\nRecommended Dosage:
\nStandard Dose: 9.75 mg administered as a single injection.
\nAlternative Doses: 5.25 mg or 15 mg may be considered based on clinical judgment.
\nMaximum Dosage: The maximum cumulative dose should not exceed 30 mg in a 24-hour period.
\nDosing Interval: If a second or third injection is required, allow at least 2 hours between injections.
\nAdministration:
\nAdministered by a healthcare professional.
\nPatients should be monitored for sedation and orthostatic hypotension for at least 1 hour after administration.
\n3. Mechanism of Action
\nReceptor Profile:
\nAripiprazole is an atypical antipsychotic with high affinity for dopamine D2 and serotonin 5-HT1A receptors, and moderate affinity for 5-HT2A receptors.
\nPartial Agonist Activity:
\nActs as a partial agonist at D2 and 5-HT1A receptors.
\nActs as an antagonist at 5-HT2A receptors.
\nClinical Effect:
\nBy modulating dopamine and serotonin transmission, it reduces agitation, aggression, and irritability associated with psychosis and mania.
\n4. Safety and Warnings
\nIncreased Mortality in Elderly with Dementia (Boxed Warning):
\nElderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
\nSuicidal Thoughts and Behaviors:
\nMonitor for the emergence of suicidal ideation and behavior.
\nOrthostatic Hypotension:
\nCan cause a drop in blood pressure upon standing, leading to syncope (fainting).
\nNeuroleptic Malignant Syndrome (NMS):
\nMonitor for NMS, a potentially fatal reaction.
\nTardive Dyskinesia:
\nRisk of developing abnormal involuntary movements.
\n5.Adverse Reactions
\nMost Common:
\nNausea, headache, vomiting, dizziness, anxiety, and restlessness.
\nInjection Site:
\nPain at the injection site may occur.
\n6.Drug Interactions
\nCYP3A4 and CYP2D6 Substrate:
\nAripiprazole is metabolized by CYP3A4 and CYP2D6 enzymes.
\nStrong CYP3A4 Inhibitors:
\nDose reduction is required (e.g., ketoconazole, itraconazole).
\nStrong CYP2D6 Inhibitors:
\nDose reduction is required (e.g., quinidine, fluoxetine).
\nCYP3A4 Inducers:
\nDose increase is required (e.g., carbamazepine, rifampin).
\n7.Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Aripiprazole.
\nAvailable Strength: 9.75 mg\/1.3 mL (single-dose vial).
\nAppearance: Clear, colorless to pale yellow solution.
\nStorage: Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u201330\u00b0C (59\u201386\u00b0F).<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name:\u5b89\u5f8b\u51e1\u8fc8\u8fbe \u00ae(Abilify Maintena\u00ae)
\nGeneric Name: Aripiprazole
\nStrength: 0.3 g (300 mg) per vial (calculated as C\u2082\u2083H\u2082\u2087Cl\u2082N\u2083O\u2082)
\nManufacturer: Sichuan Otsuka Pharmaceutical Co., Ltd.
\nMarketing Authorization Holder: Zhejiang Otsuka Pharmaceutical Co., Ltd.
\nApproval Date in China: May 23, 2023
\nRegistration Number: H20230024
\nStorage: Store at controlled room temperature (15\u201330\u00b0C \/ 59\u201386\u00b0F), protect from light and moisture. Reconstituted suspension should be used immediately. Refer to the package insert for detailed storage and handling instructions.<\/p>\n
Price&Cost:Contact Us now for the best price of Aripiprazole (Abilify Maintena\uff09<\/p>\n","protected":false},"featured_media":4072,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[25,73],"product_tag":[],"class_list":["post-4071","product","type-product","status-publish","has-post-thumbnail","product_cat-injection","product_cat-chinese-innovative-drug","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n